top of page
Bariatric Embolization for Obesity Management with Dr. Clifford Weiss, Dr. Michael Barraza on the BackTable VI Podcast
00:00 / 01:04

Save your progress. Continue watching on the BackTable app.

BackTable Vascular & Interventional

Episode # 475  •  20 Aug 2024

Bariatric Embolization for Obesity Management

While GLP-1 agonists continue to gain popularity in the medical management of diabetes and obesity, Dr. Cliff Weiss is exploring bariatric arterial embolization (BAE) as an adjunctive therapy to help patients sustain weight loss. Dr. Weiss, the Director of IR Research at Johns Hopkins, joins the show to discuss the techniques and impacts of BAE for obesity treatment.

This podcast is supported by

Reflow Medical

Timestamps

00:00 - Introduction
03:21 - Early Research and Development of BAE
07:39 - Potential Role of BAE in Obesity Treatment
16:03 - Procedure Details
25:28 - Post-Procedure Care and Patient Management
28:06 - Insights from the BEAT Obesity Trial
33:38 - BEATLES Trial
37:38 - Combination Therapy for Obesity

Resources

You may also like

See more of the content that's relevant to your practice.

More about this episode

Dr. Weiss outlines his initial research interest in gastric embolization of the fundus to reduce ghrelin production. He began by studying the use of sclerosants for embolization but later shifted to using embolic spheres. BAE involves the targeted embolization of the left gastric artery, with or without the left gastroepiploic artery, using 300-500 micron embolic spheres. Dr. Weiss also employs a dilute mixture of spheres and a vasodilator to achieve distal arterial penetration.

He describes the role of BAE in conjunction with existing surgical and pharmaceutical treatments. According to his experience, patients undergoing BAE achieve maximum weight loss 6-9 months after the procedure and can maintain this weight when they follow up in a weight management clinic. Additionally, Dr. Weiss reviews data from BAE studies, including the BEAT Obesity Trial and the recent BEATLES Trial.

The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.

bottom of page